Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine in Patients with Heart Failure with Preserved Ejection Fraction
2009-017168-17Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Ranolazine with Placebo (2 arms). Primary endpoints: Exploratory diastolic function endpoints and Safety and tolerability through Day 28. Started Jan 2010; status: completed.
02
Drugs
ranolazine
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2009-017168-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017168-17.